Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
Joel M. Gelfand, Daniel B. Shin, Abass Alavi, et al.
Journal of Investigative Dermatology (2019) Vol. 140, Iss. 1, pp. 85-93.e2
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu, Sheng Li, Shuni Ying, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 227
Comparison of Biologics and Oral Treatments for Plaque Psoriasis
April W. Armstrong, L. Puig, Avani Joshi, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 3, pp. 258-258
Open Access | Times Cited: 218
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 146
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2021) Vol. 2021, Iss. 12
Open Access | Times Cited: 135
Cardiovascular Risk in Patients With Psoriasis
Michael Garshick, Nicole L. Ward, James G. Krueger, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 13, pp. 1670-1680
Open Access | Times Cited: 127
Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Jashin J. Wu, Arthur Kavanaugh, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 6, pp. 797-806
Open Access | Times Cited: 112
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 109
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 92
Disease modification in inflammatory skin disorders: opportunities and challenges
Thomas Bieber
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 662-680
Closed Access | Times Cited: 44
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
L. Sawyer, K Malottki, Celia Sabry-Grant, et al.
PLoS ONE (2019) Vol. 14, Iss. 8, pp. e0220868-e0220868
Open Access | Times Cited: 139
Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches
Anna Campanati, Andrea Marani, Emanuela Martina, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1511-1511
Open Access | Times Cited: 80
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab
F. Poizeau, Emmanuel Nowak, Sandrine Kerbrat, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 11, pp. 1208-1208
Open Access | Times Cited: 77
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)
Joel M. Gelfand, Daniel B. Shin, Kristina Callis Duffin, et al.
Journal of Investigative Dermatology (2020) Vol. 140, Iss. 9, pp. 1784-1793.e2
Open Access | Times Cited: 75
Aberrations in Lipid Expression and Metabolism in Psoriasis
Julia Nowowiejska, Anna Baran, Iwona Flisiak
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6561-6561
Open Access | Times Cited: 64
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 885-905
Open Access | Times Cited: 63
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis
Paolo Gisondi, Maria Concetta Fargnoli, Paolo Amerio, et al.
Italian Journal of Dermatology and Venereology (2022) Vol. 157
Open Access | Times Cited: 63
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
Alan Menter, Gerald G. Krueger, So Yeon Paek, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 385-400
Open Access | Times Cited: 61
Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review
Annika Smith, Ayşegül Yağcı, Deborah Yi, et al.
Dermatology and Therapy (2025)
Open Access | Times Cited: 1
Potential Immunological Links Between Psoriasis and Cardiovascular Disease
Aparna Sajja, Aditya A. Joshi, Heather Teague, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 63
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
Paras Karmacharya, Alexis Ogdie, Lihi Eder
Therapeutic Advances in Musculoskeletal Disease (2021) Vol. 13
Open Access | Times Cited: 54
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Neil H. Shear, Keith A. Betts, Ahmed M. Soliman, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 3, pp. 572-581
Open Access | Times Cited: 50
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics
Brittany Weber, Joseph F. Merola, M. Elaine Husni, et al.
Current Atherosclerosis Reports (2021) Vol. 23, Iss. 11
Open Access | Times Cited: 45
Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Álvaro González‐Cantero, ­Daniel ­Ortega‐Quijano, Noelia Álvarez‐Díaz, et al.
Journal of Investigative Dermatology (2021) Vol. 141, Iss. 10, pp. 2402-2411
Open Access | Times Cited: 42
Comorbidity in Adult Psoriasis: Considerations for the Clinician
Christine Daugaard, Lars Iversen, Kasper Fjellhaugen Hjuler
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 139-150
Open Access | Times Cited: 36
Cardiovascular comorbidity in psoriasis – psoriatic inflammation is more than just skin deep
Katharina S. Kommoss, Alexander Enk, Mathias Heikenwälder, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 21, Iss. 7, pp. 718-725
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top